Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624918 · ClinicalTrials.gov registry record · Phase 2
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Adenocarcinoma and Resectable Pancreatic Cancer, sponsored by Ashish Manne.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT05624918 is a Phase 2 study of Pancreatic Adenocarcinoma and Resectable Pancreatic Cancer that is actively recruiting participants, run by Ashish Manne. The registered enrollment target is 38 participants, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05624918, a Phase 2 study of Pancreatic Adenocarcinoma and Resectable Pancreatic Cancer, is actively recruiting participants, sponsored by Ashish Manne.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patients will undergo restaging by CT or MRI. Patients with stable disease or better will undergo surgery for resection within 8 weeks following completion of initial chemotherapy although enrolling sites are encouraged to perform resection within 4 weeks of Cycle 3 D15 of therapy. If resection yields R0 or R1, patients will begin an additional 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment within 8 weeks of surgery. Based on available literature, it is expected that a percentage of patients will not undergo resection either due to disease progression or due to toxicities/ complications of the neoadjuvant segment of therapy. These patients will be included in the evaluable patients for both co-primary endpoints as well as the secondary endpoints including ORR, adverse events, and OS.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab paclitaxel
- DEVICE NovoTTF-200T(P)
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624918
The ClinicalTrials.gov registry entry for NCT05624918 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Ashish Manne, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT05624918 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05624918 about?
NCT05624918 is a clinical study titled "A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma". This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patient...
What is the current status of trial NCT05624918?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2024-07-01. Estimated completion is 2028-08.
What conditions does trial NCT05624918 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer.
What interventions are being tested in trial NCT05624918?
The interventions under investigation include: Gemcitabine (DRUG), Nab paclitaxel (DRUG), NovoTTF-200T(P) (DEVICE).
Who is sponsoring clinical trial NCT05624918?
This trial is sponsored by Ashish Manne, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624918 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.